Celularity Inc (NASDAQ:CELU) — Market Cap & Net Worth
Market Cap & Net Worth: Celularity Inc (CELU)
Celularity Inc (NASDAQ:CELU) has a market capitalization of $36.05 Million ($36.05 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23216 globally and #5070 in its home market, demonstrating a -11.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Celularity Inc's stock price $1.27 by its total outstanding shares 28837787 (28.84 Million). Also see Celularity Inc total assets for a full breakdown of the balance sheet.
Celularity Inc Market Cap History: 2019 to 2026
Celularity Inc's market capitalization history from 2019 to 2026. Data shows change from $2.87 Billion to $36.62 Million (-45.71% CAGR). Also see CELU cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Celularity Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #663 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2192 of 3165 |
Weight: Celularity Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Celularity Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Celularity Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Celularity Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.11x
Celularity Inc's market cap is 1.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $2.87 Billion | $21.15 Million | -$211.88 Million | 135.69x | N/A |
| 2020 | $3.17 Billion | $14.28 Million | -$208.23 Million | 222.17x | N/A |
| 2021 | $1.48 Billion | $21.34 Million | -$100.12 Million | 69.21x | N/A |
| 2022 | $372.01 Million | $17.98 Million | $14.19 Million | 20.70x | 26.21x |
| 2023 | $71.23 Million | $22.77 Million | -$196.29 Million | 3.13x | N/A |
| 2024 | $59.98 Million | $54.22 Million | -$57.89 Million | 1.11x | N/A |
Competitor Companies of CELU by Market Capitalization
Companies near Celularity Inc in the global market cap rankings as of September 18, 2026. Review Celularity Inc tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Celularity Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Celularity Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Celularity Inc's market cap moved from $2.87 Billion to $ 36.62 Million, with a yearly change of -45.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $36.62 Million | +14.41% |
| 2025 | $32.01 Million | -46.63% |
| 2024 | $59.98 Million | -15.79% |
| 2023 | $71.23 Million | -80.85% |
| 2022 | $372.01 Million | -74.80% |
| 2021 | $1.48 Billion | -53.45% |
| 2020 | $3.17 Billion | +10.55% |
| 2019 | $2.87 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Celularity Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.05 Million USD |
| MoneyControl | $36.05 Million USD |
| MarketWatch | $36.05 Million USD |
| marketcap.company | $36.05 Million USD |
| Reuters | $36.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Celularity Inc
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioB… Read more